GHO Capital Partners, the London-based private equity firm that targets early stage and mid-market investments, has agreed to sell VISUfarma, its pan-European ophthalmic pharmaceutical company, to Indian pharmaceutical group Lupin for €190 million (~ ₹2,000 crore).



